Cancer in patients on Dapagliflozin and other antidiabetic treatment

Trial Identifier: D1690R00007
Sponsor: AstraZeneca
NCTID:: NCT02695121
Start Date: January 2017
Primary Completion Date: September 2024
Study Completion Date: February 2025
Condition: Cancer - Other; Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Netherlands Utrecht, Netherlands
United Kingdom London, United Kingdom
United States of America, DE Wilmington, DE, United States of America
United States of America, Washington DC Washington DC, United States of America